source
- Arpeggio Biosciences shuts down after Nrf2 drug program encounters off-target toxicityArpeggio Biosciences, founded in 2018 in Boulder, Colorado, built its platform around a large nascent‑RNA sequence database and aimed to develop a small‑molecule degrader of the Nrf2 transcription…
- aTyr Pharma cuts 60% of staff to fund second phase 3 trial of lung disease drug efzofitimodaTyr Pharma announced it will reduce its workforce by about 60%, leaving roughly 20 employees, to reallocate resources toward its lung disease program. The cut follows the company's previous phase…